Forte Biosciences, Inc. (FBRX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$58.2M
Cash & Equivalents
$18.8M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$899M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-31 | Phase1 Readout | — |
| 2027-02-01 | Phase1 Readout | — |
| 2027-02-28 | Phase2 Readout | — |
| 2027-03-10 | Phase1 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06982963 | Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease | PHASE2 | Recruiting | 100 |
| NCT07205159 | A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. | PHASE1 | Recruiting | 32 |
| NCT06905873 | A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo | PHASE1 | Recruiting | 64 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-07-09 | 8-K | Forte Biosciences, Inc. (FBRX) (CIK 0001419041) - EX-99.2 | EDGAR |